We still expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031.
We still expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031.
Second Floor
Apollon Building
74 Agios Athanasios Avenue
4102 Agios Athanasios
Cyprus
PO Box 53720
3317 Limassol
Cyprus
Tel: ++357 25 82 82 92
© 2025 3DGlobal.
Webdesign: topright design agency